NICE is dead; long live NICE

BMJ (Online)

Volumn 346, Issue 7905, 2013, Pages

  Chinthapalli, Krishna ^a  

^a British Medical Journal Technology Assessment Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHANGE MANAGEMENT; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; MEDICAL SOCIETY; MEDICOLEGAL ASPECT; ORGANIZATIONAL EFFICIENCY; POLITICAL PARTICIPATION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ACADEMIES AND INSTITUTES; DECISION MAKING, ORGANIZATIONAL; GOVERNMENT AGENCIES; GREAT BRITAIN; HUMANS; NATIONAL HEALTH PROGRAMS; POLICY MAKING;

EID: 84877621627     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f2546     Document Type: Article

References (48)

1. BBC News. Relenza: the implications. BBC News 1999 Oct. 1. http://news.bbc.co.uk/1/hi/health/462721.stm.
2. BBC News. Drugs industry hits back. BBC News 1998. http://news.bbc.co.uk/ 1/hi/health/216310.stm. Nov. 17.
3. National Institute for Clinical Excellence (Establishment and Constitution) Order 1999. www.parliament.the-stationery-office.co.uk/pa/ cm199899/cmstand/deleg3/st990311/90311s01.htm.
4. National Institute for Health and Clinical Excellence. Health Act makes NICE stronger than ever before. 2012. www.nice.org.uk/newsroom/news/ HealthActMakesNICEStrongerThanEverBefore.jsp.
5. Written evidence from Pfizer Ltd (NICE 62). House of Commons Health Committee. 2012. www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/ 782/782vw56.htm.
6. Written evidence from GlaxoSmithKline (NICE 54). House of Commons Health Committee. 2012. www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/ 782/782vw49.htm.
7. Department of Health. A first class service: quality in the new NHS.; 1998. www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/ digitalasset/dh-4044941.pdf.
8. House of Commons Health Committee. National Institute for Health and Clinical Excellence. 2007. www.publications.parliament.uk/pa/cm200708/cmselect/ cmhealth/27/27.pdf.
9. Written evidence from the European Medicines Group (NICE 31). House of Commons Health Committee. 2012. www.publications.parliament.uk/pa/cm201213/ cmselect/cmhealth/782/782vw28.htm.
10. NICE. Technology appraisal topic selection. 2013. http://www.nice.org.uk/ getinvolved/topicselection/TechnologyAppraisalTopicSelection.jsp.
11. Written evidence from the MS Society (NICE 36). House of Commons Health Committee. 2012. www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/ 782/782vw32.htm.
12. Written Evidence from the British Association for Counselling and Psychotherapy (NICE 39). House of Commons Health Committee. 2012. www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/782/782vw34.htm.
13. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Clin Med 2008;8:579-88.
14. Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677.
15. McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 2010;340:c1786.
16. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010;340:c1672.
17. Compston A. Commentary: scheme has benefited patients. BMJ 2010;340:c2707.
18. Hewitt "has left NHS toothless." BBC News 2005 Nov. 10. http://news.bbc.co.uk/1/hi/health/4422662.stm.
19. Herceptin and early breast cancer: a moment for caution. Lancet 2005;366:1673.
20. Sikora K. A Stalinist NHS quango and British cancer victims denied drugs available in Europe. Daily Mail 2009 Nov. 20. www.dailymail.co.uk/debate/ article-1229443/KAROLSIKORA-A-Stalinist-NHS-quango-British-cancer-victims- denied-drugs-available-Europe.html.
21. Sikora K. The big C: cancer treatment is increasingly unaffordable. Telegraph 2011 Sep. 27. www.telegraph.co.uk/health/healthnews/8791979/The-big-C- cancer-treatment-isincreasinglyunaffordable.html.
22. Department of Health. The cancer drugs fund: guidance to support operation of the cancer drugs fund in 2012-13. 2012. www.gov.uk/government/ uploads/system/uploads/attachment-data/file/152364/dh-133683.pdf.pdf.
23. Association of the British Pharmaceutical Industry. The cancer drugs fund: consultation response. 2010. www.abpi.org.uk/our-work/policy- parliamentary/Documents/CDFresponseabpi.pdf.
24. NICE. Technology appraisals: full table of recommendations. 2013. www.nice.org.uk/media/7D1/EA/NICE-TA-Decision-Summary-March-2013.doc.
25. Raftery J. Review of NICE's recommendations, 1999-2005. BMJ 2006;332:1266-8. (Pubitemid 44365421)
26. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;302:1437-43.
27. Ford JA, Waugh N, Sharma P, Sculpher M, Walker A. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. BMJ Open 2012;2:e000671.
28. World Health Organization. The world medicines situation 2011-medicine expenditures. WHO Press, 2011.
29. Association of the British Pharmaceutical Industry. Global pharmaceutical industry and market. 2012. www.abpi.org.uk/industry-info/knowledge-hub/global- industry/Pages/industrymarket-.aspx.
30. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ 2012;345:e4348.
31. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ. 2006;333:1118-20. (Pubitemid 44863653)
32. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7. (Pubitemid 39013284)
33. Burström K, Johannesson M, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006;76:359-70. (Pubitemid 46137849)
34. Supplementary memorandum by ABPI (NICE 72A). House of Commons Health Committee, 2007. www.publications.parliament.uk/pa/cm200708/cmselect/cmhealth/ 27/27we15.htm.
35. Association of the British Pharmaceutical Industry. Submission to Sir Ian Kennedy's review. 2009. www.nice.org.uk/media/B4E/71/KennedyABPI.pdf.
36. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ. 2007;335:358-9. (Pubitemid 47359304)
37. Written evidence from Karl Claxton, Steve Martin, Marta Soares, Nigel Rice, Eldon Spackman, Sebastian Hinde, Peter C Smith and Mark Sculpher (NICE 61). House of Commons Health Committee 2012. www.publications.parliament.uk/pa/ cm201213/cmselect/cmhealth/782/782vw55.htm.
38. Department of Health. Pharmaceutical Price Regulation Scheme: 11th report to parliament. 2012. www.gov.uk/government/uploads/system/uploads/attachment- data/file/146828/dh-132793.pdf.pdf.
39. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008;336:251-4. (Pubitemid 351251624)
40. Government's response to the health select committee's eighth report of session 2012-13 on the National Institute for Health and Clinical Excellence. 2013. www.official-documents.gov.uk/document/cm85/8568/8568.pdf.
41. Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA 2005;294:2630-2. (Pubitemid 41697253)
42. NICE. Fact sheet: clinical guidelines. 2010. www.nice.org.uk/mediacentre/ factsheets/clinicalguidelines.jsp.
43. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005;187:248-55. (Pubitemid 41306106)
44. Department of Health. Innovation health and wealth, accelerating adoption and diffusion in the NHS. 2011. www.tin.nhs.uk/EasysiteWeb/getresource.axd? AssetID=44764&type=full&servicetype=Attachment.
45. Department of Health. Creating Change, IHW One Year On. 2012. www.gov.uk/government/uploads/system/uploads/attachment-data/file/127284/ Creating-Change-IHWOne-Year-On-FINAL.pdf.pdf.
46. Health and Social Care Information Centre. NICE technology appraisals in the NHS in England 2011; experimental statistics-innovation scorecard. 2013. https://catalogue.ic.nhs.uk/publications/prescribing/secondary/ nice-tech-apps-eng-2011-exp-inno-scor-rep/nice-tech-apps-eng-2011-exp-inno-scor- rep.pdf.
47. Association of the British Pharmaceutical Industry. New innovation scorecard shows the extent of regional variation in the NHS. 2013. www.abpi.org.uk/media-centre/newsreleases/2013/Pages/100113.aspx.
48. Nicholson D. Innovation health and wealth publication of NHS formularies. 2012. www.gov.uk/government/uploads/system/uploads/attachment-data/file/126929/ NHSCEformulariesletter-August-2012.pdf.pdf.